World game at war: why some European nations have threatened a World Cup boycott 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SAN DIEGO, April 26, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University.
The CD3E model expresses the human form of CD3E and is phenotypically normal with levels of T, B, and NK cells comparable to control. These features make it an ideal model for determining the efficacy of CD3 targeted T cell redirecting therapies through direct assessment of T cell activation, antigen recognition and related intracellular signal transduction pathways.
“Data generated from our new CD3E models demonstrate their unique ability to guide development of bispecific T cell engagers and other T cell redirecting therapies,” said Dr. Davy Ouyang, Director of Translational Oncology at CrownBio. “We are very excited about the potential these innovative models have to uncover new insights in the discovery and development of cutting-edge I/O agents.”
Learn more about CrownBio’s new CD3E model by visiting https://www.crownbio.com/immuno-oncology/hugemm/cd3e-mouse-model
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About NBRI of Nanjing University
NBRI is a leading company in China to provide high-quality human disease related animal models for biomedical community as well as pharmaceutical companies. With more than 10 years’ practice, NBRI has the vision and is striving to become world-class one-stop service center for generating, phenotyping and distributing the customized genetically engineering murine models for partners all across the world.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
